- Home
- IDR vs EDIT Comparison
IDR vs EDIT Comparison
Compare IDR & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IDR | EDIT |
|---|---|---|
| Founded | 1996 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 481.0M | 422.3M |
| IPO Year | 2000 | 2016 |
Fundamental Metrics
Financial Performance| Metric | IDR | EDIT |
|---|---|---|
| Price | $18.53 | $2.17 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $6.10 |
| AVG Volume (30 Days) | 231.9K | ★ 2.1M |
| Earning Date | 11-24-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 70.15 | 37.50 |
| EPS | ★ 0.63 | N/A |
| Revenue | ★ $42,406,253.00 | $31,937,000.00 |
| Revenue This Year | $27.10 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $30.12 | ★ N/A |
| Revenue Growth | 64.59 | ★ 132.64 |
| 52 Week Low | $18.55 | $1.66 |
| 52 Week High | $53.30 | $3.94 |
Technical Indicators
Market Signals| Indicator | IDR | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 36.15 | 38.65 |
| Support Level | N/A | $1.82 |
| Resistance Level | $35.52 | $2.29 |
| Average True Range (ATR) | 1.21 | 0.24 |
| MACD | 0.21 | -0.05 |
| Stochastic Oscillator | 7.16 | 15.58 |
Price Performance
Historical ComparisonAbout IDR Idaho Strategic Resources Inc.
Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. The Company's primary business is exploring for, developing, and extracting gold, and to a lesser extent, silver, and base metal mineral resources in the greater Coeur d'Alene Mining District of North Idaho. The Company produces gold at the Golden Chest Mine located in the Murray Gold Belt area of the world-class Coeur d'Alene Mining District, north of the prolific Silver Valley.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.